- After-Shows
- Alternative
- Animals
- Animation
- Arts
- Astronomy
- Automotive
- Aviation
- Baseball
- Basketball
- Beauty
- Books
- Buddhism
- Business
- Careers
- Chemistry
- Christianity
- Climate
- Comedy
- Commentary
- Courses
- Crafts
- Cricket
- Cryptocurrency
- Culture
- Daily
- Design
- Documentary
- Drama
- Earth
- Education
- Entertainment
- Entrepreneurship
- Family
- Fantasy
- Fashion
- Fiction
- Film
- Fitness
- Food
- Football
- Games
- Garden
- Golf
- Government
- Health
- Hinduism
- History
- Hobbies
- Hockey
- Home
- How-To
- Improv
- Interviews
- Investing
- Islam
- Journals
- Judaism
- Kids
- Language
- Learning
- Leisure
- Life
- Management
- Manga
- Marketing
- Mathematics
- Medicine
- Mental
- Music
- Natural
- Nature
- News
- Non-Profit
- Nutrition
- Parenting
- Performing
- Personal
- Pets
- Philosophy
- Physics
- Places
- Politics
- Relationships
- Religion
- Reviews
- Role-Playing
- Rugby
- Running
- Science
- Self-Improvement
- Sexuality
- Soccer
- Social
- Society
- Spirituality
- Sports
- Stand-Up
- Stories
- Swimming
- TV
- Tabletop
- Technology
- Tennis
- Travel
- True Crime
- Episode-Games
- Visual
- Volleyball
- Weather
- Wilderness
- Wrestling
- Other
Adam S. Wenick, MD, PhD - Keeping Sight of Adherence with VEGF-Targeted Therapy: Individualized Dosing Strategies to Improve Care for nAMD
Please visit answersincme.com/AXS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Adam S. Wenick, an expert in ophthalmology, discusses treatment adherence in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal vascular endothelial growth factor– (VEGF-) targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Review patient counseling approaches to improve treatment adherence to intravitreal VEGF-targeted therapies for nAMD.
